Next Article in Journal
Nomenclature- and Database-Compatible Names for the Two Ebola Virus Variants that Emerged in Guinea and the Democratic Republic of the Congo in 2014
Next Article in Special Issue
Genotypic Analysis of Kaposi’s Sarcoma-Associated Herpesvirus from Patients with Kaposi’s Sarcoma in Xinjiang, China
Previous Article in Journal
Flavivirus-Mosquito Interactions
Previous Article in Special Issue
Twenty Years of KSHV
Article Menu

Export Article

Open AccessReview
Viruses 2014, 6(11), 4731-4759; doi:10.3390/v6114731

KSHV Targeted Therapy: An Update on Inhibitors of Viral Lytic Replication

Rega Institute for Medical Research, KU Leuven, B-3000 Leuven, Belgium
*
Author to whom correspondence should be addressed.
Received: 23 July 2014 / Revised: 7 November 2014 / Accepted: 17 November 2014 / Published: 24 November 2014
(This article belongs to the Special Issue Kaposi's Sarcoma-Associated Herpesvirus)
View Full-Text   |   Download PDF [685 KB, uploaded 12 May 2015]   |  

Abstract

Kaposi’s sarcoma-associated herpesvirus (KSHV) is the causative agent of Kaposi’s sarcoma, primary effusion lymphoma and multicentric Castleman’s disease. Since the discovery of KSHV 20 years ago, there is still no standard treatment and the management of virus-associated malignancies remains toxic and incompletely efficacious. As the majority of tumor cells are latently infected with KSHV, currently marketed antivirals that target the virus lytic cycle have shown inconsistent results in clinic. Nevertheless, lytic replication plays a major role in disease progression and virus dissemination. Case reports and retrospective studies have pointed out the benefit of antiviral therapy in the treatment and prevention of KSHV-associated diseases. As a consequence, potent and selective antivirals are needed. This review focuses on the anti-KSHV activity, mode of action and current status of antiviral drugs targeting KSHV lytic cycle. Among these drugs, different subclasses of viral DNA polymerase inhibitors and compounds that do not target the viral DNA polymerase are being discussed. We also cover molecules that target cellular kinases, as well as the potential of new drug targets and animal models for antiviral testing. View Full-Text
Keywords: KSHV; antiviral; nucleoside analog; DNA polymerase inhibitors; lytic cycle; ganciclovir; cidofovir; foscarnet KSHV; antiviral; nucleoside analog; DNA polymerase inhibitors; lytic cycle; ganciclovir; cidofovir; foscarnet
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Coen, N.; Duraffour, S.; Snoeck, R.; Andrei, G. KSHV Targeted Therapy: An Update on Inhibitors of Viral Lytic Replication. Viruses 2014, 6, 4731-4759.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Viruses EISSN 1999-4915 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top